KYMR News & Events

Kymera Therapeutics announced that it recently initiated dosing in its BREADTH Phase 2b clinical trial evaluating KT-621, an oral, highly selective, potent degrader of STAT6, in patients with moderate to severe eosinophilic asthma. The Company expects to report data from the BREADTH trial in late-2027.

Kymera Therapeutics announced its anticipated 2026 preclinical and clinical milestones across its oral immunology pipeline. Key highlights: KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027; KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027; KT-579 Phase 1 HV clinical trial expected to start in 1Q26, with data expected in 2H26; Advancing at least one new development candidate towards IND for a first-in-class, oral immunology program in 2026